Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

FCA was determined using a dual-tracer stable-calcium isotope method.

FCA and 25(OH)D were similar between treatment groups at baseline (0.31 ± 0.12 ng/mL and 19.8 ± 4.7 ng/mL, respectively).

Who Took Part

The study group was 56 women.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Alendronate, Bone Density Conservation Agents, Calcium, Cholecalciferol, Endpoint Determination and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 56 women.

The publication is from 2011 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.